65,437 trials
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B) — 48.8; 39.5 percentage of participants — p=0.510
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13 — -18.5; -9.7 mg/dL — p=0.245
Atrial Fibrillation · Thoracic Surgery
Primary: Clinically Significant Atrial Fibrillation — 5; 6 Participants
Prostate Cancer
Primary: Overall Survival — 88.7; 93.3 percentage of participants — p=0.0398
Juvenile Neuronal Ceroid Lipofuscinosis
Primary: Tolerability - Number of Participants Who Completed Each Arm on Assigned Study Drug Dose — 17; 19 Participants — p=0.21
Pain · Weakness · Cramps
Primary: Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use — 53; 65 % of participants with pain reduction
Breast Cancer
Primary: Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery — 57.8; 78.7 μg/mL
Healthy
Primary: Area Under the Concentration-time Curve of the Analyte BI-113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 936; 924; 648…
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.90; -0.89 percentage of glycosylated haemoglobin — p=<0.0001
Diabetes Mellitus, Type 2 · Exocrine Pancreatic Insufficiency
Primary: Part A: Serum TG Level. — 2.07; 1.68; 2.00 millimole per litre (mmol/L)
Anemia
Primary: Percentage of Participants With Lesser Than or Equal to One Gram Per Deciliter Decrease in Average Hemoglobin From Baseline and Maintaining Average Hemoglobin Level…
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -0.43; -0.14 Percentage of glycosylated haemoglobin — p=0.427
Pulmonary Disease, Chronic Obstructive
Primary: Number (%) of Patients With Drug-related Adverse Events (AEs) — 7; 7; 10; 14 percentage of participants
Visual Acuity
Primary: Higher Order Root Mean Square (HO RMS) - Near Target in Downgaze With Natural Blinking — 0.159; 0.142 microns
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 33.3; 33.3; 22.2; 88.9 percentage of participants